Dyne Therapeutics (DYN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.37B and a free-cash-flow yield of -18.3%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 2.7/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Lagging · -12.3% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-61.9%
How far the last close sits under the highest price of the past five years.
Market cap
$3.37B
Trailing P/E
—
Price / book
4.3
Price / sales
—
FCF yield
-18.3%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
1.1
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
DYN earnings
Next report: Mar 1, 2027 (Q4 2026, EPS estimate -$0.91).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 5, 2026
-$1.06
-$0.88
-20.4%
$0
Q2 2026
Jul 29, 2026
-$1.08
-$0.75
-44.0%
$0
Q1 2026
May 11, 2026
-$0.73
-$0.78
+6.4%
$0
Q4 2025
Mar 2, 2026
-$0.73
-$0.76
+4.0%
$0
DYN analyst price target
Median target $36.00 from 15 analysts, ranging $10.00 – $50.00.
Nama's AI scorecard currently rates Dyne Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does DYN report earnings?
Dyne Therapeutics's next scheduled report is on Mar 1, 2027. Analysts expect EPS of -$0.91.
What is the DYN price target?
The median analyst price target from 15 analysts is $36.00, with a range of $10.00 – $50.00.
Is DYN Shariah compliant?
Nama's AAOIFI-style screen reads Dyne Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.